Abicipar is a DARPin® therapeutic candidate designed to inhibit vascular endothelial growth factor (VEGF). It is at the registrational stage as an investigational candidate for the treatment of neovascular (wet) age-related macular degeneration (nAMD). Abicipar is also currently under investigation in diabetic macular edema, or DME. Abicipar is designed to remain in the eye longer than current treatments and consequently offers the potential for less frequent dosing. Molecular Partners exclusively licensed abicipar to Allergan in May 2011 on a worldwide basis in the field of ophthalmology.
Current anti-VEGF treatments are injected on a monthly, bi-monthly and — only in a subset of patents — on a quarterly basis. Less frequent injections are a key advantage for patients.
An anti-VEGF with high potency and long ocular half-life would allow less frequent injections compared to standard therapies.
Abicipar has been engineered for a long half-life in the eye and highest potency. Phase 3 results have demonstrated that quarterly injections are equivalent to monthly injections of Lucentis®.